About kymera therapeutics inc - KYMR
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
KYMR At a Glance
Kymera Therapeutics, Inc.
500 North Beacon Street
Watertown, Massachusetts 02472
| Phone | 1-857-285-5300 | Revenue | 47.07M | |
| Industry | Biotechnology | Net Income | -223,858,000.00 | |
| Sector | Health Technology | Employees | 188 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KYMR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 64.136 |
| Price to Book Ratio | 3.124 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.50 |
| Enterprise Value to Sales | 55.618 |
| Total Debt to Enterprise Value | 0.034 |
KYMR Efficiency
| Revenue/Employee | 250,382.979 |
| Income Per Employee | -1,190,734.043 |
| Receivables Turnover | 49.706 |
| Total Asset Turnover | 0.061 |
KYMR Liquidity
| Current Ratio | 7.53 |
| Quick Ratio | 7.53 |
| Cash Ratio | 7.212 |
KYMR Profitability
| Gross Margin | 84.337 |
| Operating Margin | -545.356 |
| Pretax Margin | -475.565 |
| Net Margin | -475.565 |
| Return on Assets | -28.814 |
| Return on Equity | -36.382 |
| Return on Total Capital | -24.243 |
| Return on Invested Capital | -32.36 |
KYMR Capital Structure
| Total Debt to Total Equity | 10.503 |
| Total Debt to Total Capital | 9.504 |
| Total Debt to Total Assets | 8.973 |
| Long-Term Debt to Equity | 8.933 |
| Long-Term Debt to Total Capital | 8.084 |